(2S,4S)-4-(4-(2-(cyclopropanecarboxamido)thiazolo[5,4-b]pyridin-5-yl)-1H-1,2,3-triazol-1-yl)-N-(3,4-difluorophenyl)pyrrolidine-2-carboxamide

ID: ALA5194721

Chembl Id: CHEMBL5194721

PubChem CID: 168288878

Max Phase: Preclinical

Molecular Formula: C23H20F2N8O2S

Molecular Weight: 510.53

Associated Items:

Names and Identifiers

Canonical SMILES:  O=C(Nc1nc2ccc(-c3cn([C@@H]4CN[C@H](C(=O)Nc5ccc(F)c(F)c5)C4)nn3)nc2s1)C1CC1

Standard InChI:  InChI=1S/C23H20F2N8O2S/c24-14-4-3-12(7-15(14)25)27-21(35)18-8-13(9-26-18)33-10-19(31-32-33)16-5-6-17-22(28-16)36-23(29-17)30-20(34)11-1-2-11/h3-7,10-11,13,18,26H,1-2,8-9H2,(H,27,35)(H,29,30,34)/t13-,18-/m0/s1

Standard InChI Key:  QFKVEVOGGCTCKS-UGSOOPFHSA-N

Alternative Forms

  1. Parent:

    ALA5194721

    ---

Associated Targets(Human)

ABL1 Tclin Bcr/Abl fusion protein (1667 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
K562 (73714 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
K562/Adr (229 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Topical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 510.53Molecular Weight (Monoisotopic): 510.1398AlogP: 3.12#Rotatable Bonds: 6
Polar Surface Area: 126.72Molecular Species: BASEHBA: 9HBD: 3
#RO5 Violations: 1HBA (Lipinski): 10HBD (Lipinski): 3#RO5 Violations (Lipinski): 1
CX Acidic pKa: 7.88CX Basic pKa: 9.05CX LogP: 2.18CX LogD: 1.83
Aromatic Rings: 4Heavy Atoms: 36QED Weighted: 0.36Np Likeness Score: -2.22

References

1. Pan X, Liu N, Liu Y, Zhang Q, Wang K, Liu X, Zhang J..  (2022)  Design, synthesis, and biological evaluation of trizole-based heteroaromatic derivatives as Bcr-Abl kinase inhibitors.,  238  [PMID:35561654] [10.1016/j.ejmech.2022.114425]

Source